Preferred Cell Systems

Executive Summary

Preferred Cell Systems is a life sciences tools company headquartered in San Diego, providing high-quality assay kits and specialized cell culture media for researchers in cell therapy, regenerative medicine, and in vitro toxicology. Founded in 2015, the company is the exclusive manufacturer of all reagents and assays originally produced by HemoGenix, positioning itself as a critical enabler for advanced cell-based R&D. With a focus on quality and consistency, Preferred Cell Systems serves as a key supplier to academic labs, biopharma companies, and CROs developing cell therapies. The company operates in the growing cell therapy tools market, beneficiaries of increasing demand for reliable testing and manufacturing solutions. While private and with limited public financial data, the company's niche position and exclusive rights to proven HemoGenix products provide a competitive moat. Near-term growth is likely driven by expansion of its product catalog and partnerships with cell therapy developers.

Upcoming Catalysts (preview)

• Q3 2026Launch of new CAR-T potency assay kit65% success
• Q4 2026Strategic supply agreement with a leading cell therapy manufacturer50% success
• TBDExpansion of distribution into Asian markets (e.g., Japan, South Korea)55% success